PRCN-829 is our patented gene therapy and we are currently developing gene therapy options for treating ALD, Diabetes type 2, ALS, Parkinson's Disease, Rheumatoid Arthritis and Wet Macular Degeneration.
We are interested in exploring the potential of adipose derived Mesenchymal stem cell therapy in combination with gene therapy to create a powerful therapeutic. An earlier study here demonstrates the potential of MSC therapy in particular for treatment of ALS. Some benefits of mesenchymal stem cells derived from the adipose tissue of the patient is no immune rejection, it is readily available and without the ethical concerns of using embryonic stem cells. We hope to explore and develop therapies based on this technique likely augmenting the stem cells ex-vivo with genes of interest to further improve regeneration of tissues.